PubMed Health⌕ Search

Biomedical subjects

A Schröck

Publications and source records attributed to A Schröck.

12 recordsLinked to original sources
PubMed1993

[Primary fallopian tube cancer--an Austrian multicenter study].

Incidence and prognostic factors of primary carcinomas of the Fallopian tubes were studied in a retrospective multi-centre analysis of 81 women during the period of 1980 to 1990. Data from 13 departments (university as well as general hospitals) were included in the present study which was designed to evaluate the state-of-the-art of diagnosis and treatment of carcinoma of the Fallopian tubes in Austria, and to compare the results with those from the literature. Stages were classified according to the modified FIGO-system for ovarian cancer; grading followed the criteria of Hu, Taylor and Hertig. The mean age of the patients was 62.1 years. Thirty-seven (45.7%) tumours were found to be in stage I, sixteen (19.8%) in stage II, nineteen (23.4%) in stage III, and nine (11.1%) tumours in stage IV. In 66 Patients, the tumour could be radically removed. The surgical method applied in 68 cases was removal of the uterus, the adnexa, and/or the omentum, or lymph nodes. Post-operatively, patients underwent an adjuvant therapy which was either irradiation (n = 32; 39.5%), or chemotherapy (n = 34; 42.0%). Fifteen patients had no therapy after operation. The five-year survival rate for stages I and II was 75% compared to 17% in stages III and IV.

Adult↗
PubMed1991

[PAP IV in pregnancy--a retrospective multicenter study].

An analysis was made of the procedure when PAP IV occurs in pregnancy. 63 patients between 1. 1. 1985 and 1. 4. 1990 from 6 main hospitals in Vienna were included in this study. In 30 cases, a cone biopsy was made during pregnancy, whilst in 33 cases, the operation was performed after delivery. In both groups, the tissue showed in the histological examination nearly the same incidence rate of carcinoma stage Ia, carcinoma in situ as well as mild, moderately severe, and severe dysplasia. A significant frequency was found for a delivery before the 35th week of gestation, if conisation was done during pregnancy. An increased negative foetal outcome was also found if the operation was performed after the 16th week of gestation. Conservative procedure showed a better foetal outcome with the same security, in that carcinoma stage Ib was never overlooked. On-target biopsy under colposcopic control, combined with a conisation 8 to 10 weeks after delivery, is therefore recommended.

Adolescent↗
PubMed1989

Low-dose ethanol for inhibition of preterm uterine activity.

Inhibition of preterm labor by tocolytic agents reduces the incidence of preterm birth. Betamimetic drugs are the most widely used tocolytic. However, they are from time to time contraindicated, their administration involves potential risks for mother and fetus, and their tocolytic effect is sometimes insufficient. Ethanol infused in intoxicating doses was the first clinically useful tocolytic agent, but because of its potential risks to the fetus, its use is now infrequent. We have examined the efficacy of ethanol infused at much lower rates, alone or in combination with ritodrine, to inhibit preterm uterine contractions. Fifty-four women between 20 and 36 weeks of gestation participated in the study. In 14, betamimetics were contraindicated and they were given ethanol alone. In 38, ritodrine infusions (0.2 gm/min) had failed to arrest preterm labor and they were then given ethanol with ritodrine (0.2 gm/min) The dose of ethanol was 0.11 gm/kg/hour on the average, which is approximately equivalent to the metabolic rate. Altogether, 64 treatments were given, 14 with ethanol alone and 50 combined with 0.2 gm/min ritodrine. In 81% of the treatments, contractions were suppressed within 15.3 hours on the average. Preterm birth (infant less than 2500 gm) was prevented in 70% of the patients. No adverse effects attributable to ethanol were observed. Treatment with low-dose intravenous infusion of ethanol is a cheap, efficacious, and low-risk method to stop preterm uterine activity and is clinically useful for prevention of preterm birth. Possible mechanism of this effect is discussed.

Drug Therapy, Combination↗
PubMed1988

[Value and significance of obstetric monitoring methods].

In a retrospective study on 224 births, 200 continuous tracings recorded during intrapartum cardiotokography were analysed for the presence of alarm signals and the incidence of fetal acidosis assessed by fetal blood sampling. Moreover, we classified the 200 monitored parturitions according to the presence of risk at the beginning and/or the appearance of alarm signals during labour into 4 groups. In 17% of the parturitions without initial risk alarm signals were subsequently recorded on CTG, whereas alarm signals occurred in 35% of high-risk births. In both groups fetal distress, as assessed by fetal blood sampling, was detected in 4%. In all investigated cases we simulated a policy of intrapartum monitoring by intermittent auscultation (IA) up to the pushing period. The CTG tracings were analysed retrospectively, whilst counting the fetal heart rate every fifteen minutes. The possible results and consequences of IA were compared with the actual results and management based on CTG alone. Vice the real management, were the decision for operative delivery after the suspected diagnosis of fetal distress had been confirmed by fetal blood sampling. The results of all three methods were compared. The superiority of CTG over IA in detecting alarming situations and fetal distress, was proven statistically. In order to prevent the unnecessary operative delivery of an infant erroneously considered to be distressed, it is mandatory to check the indication by fetal blood sampling.

Cesarean Section↗
PubMed1986

[Possibilities and value of discontinuous labor monitoring by cardiotocography. A retrospective study based on a continuous cardiotocogram].

The effectiveness of fictitious discontinuous intrapartum CTG monitoring was investigated and compared with available continuous CTG's by means of a retrospective analysis of 200 CTG tracings. CTG is a method of high sensitivity and offers, together with foetal intrapartum blood sampling, a possibility to detect foetal distress with high specificity and predictive value. From these CTG tracings the fictitious periods of time were assessed according to a certain schema to give women a possibility of being unrestricted in their activities without intrapartum monitoring while at the same time they were under satisfactory surveillance to notice sufficiently early any foetal distress that might lead to severe acidosis. The study was subdivided into 4 groups: Group 1: Patients at no risk during pregnancy and/or risk on admittance or during labour, no alarming signs from the foetus during the intrapartum period. Group 2: No risk, but with alarming signs from the foetus. Group 3: Patients at risk, no alarming signs from the foetus. Group 4: Patients at risk and with alarming signs from the foetus. The results suggest the possibility of discontinuous intrapartum monitoring according to a certain schema up to the second stage of labour, at minimum intrapartum risk for the baby, especially if there were no risks during pregnancy and at the beginning of delivery. According to these results 83% of all patients in labour would not have needed continuous CTG for more than half of the time spent in the labour ward. Only one in 6 deliveries (17%) would have required continuous monitoring.(ABSTRACT TRUNCATED AT 250 WORDS)

Female↗
PubMed1981

[Intravaginal treatment of colpitis maculosa with an oestriol-containing vaginal cream (author's transl)].

43 patients with colpitis maculosa (average age 60.2 years) were selected for an open control therapeutic study with Ortho-Gynest vaginal cream (Ortho-Cilag). The cream contains 0.5 mg of oestriol per single applicator filling. The treatment lasted from 3 to 4 weeks, success being evaluated by clinical documentation and cytological evaluation of vaginal smears before and after treatment. 10 patients (23.3%) were treated successfully, 29 (67.4%) showed a distinct improvement both clinically and cytologically, whilst the remaining 4 (9.3%) showed only moderate improvement. Hence, 39 patients (90.7%) were classified as having been successfully or partly successfully treated. Severe symptoms disappeared completely or were greatly alleviated in 91.4% cases. Moderate symptoms vanished in 59.7%. 58.1% showed a complete normalisation of the former atrophic vaginal skin. Blood spotting and reddening of the vaginal wall vanished completely. A change from dry to moist vagina occurred in 77.3% patients. Discharge vanished completely in 80.6% cases. No untoward side effects were recorded.

Administration, Topical↗